Oral solid preparation for treatment of leukemia and application thereof

A solid preparation, leukemia technology, applied in the field of medicine, can solve problems such as unproven serious problems, achieve the effects of clear components, reduce toxic and side effects, and enhance therapeutic effects

Inactive Publication Date: 2013-12-04
北京贝思康医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While rare hypocalcemia side effects were noted, but it has not been shown to cause any serious problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 The inhibitory effect of oral solid agent for gantrocytic cells in the invention

[0024] Put the human acute early early younger granular leukemia NK4 cells, chronic granulocyte leukemia K562 cells, and vitaminic acid resistance early younger granular leukemia MR-2 cells are inoculated in RPMI-1640 culture liquid, and in 37 ° C in the culture box of 5%CO2 culture boxCultivate biography, inoculate on the 96 -hole training board, add the corresponding concentration of drugs according to the group, 5 holes per concentration, and the MTT restore reaction to determine the growth suppression rate of the tumor after 48h.See Table 1.

[0025] The final concentration of the test group and administration is as follows:

[0026] Black control group: an equal volume of the volume

[0027] Group A group A: 2.4 mg / ml Dashantinib

[0028] Dashantinib group B: 9.6mg / ml Dashaidinib

[0029] Water Flying Thistle Main A Group A: 10mg / ml Water Flying Thistle

[0030] Water Flying To...

Embodiment 2

[0040] Example 2 The therapeutic effect of the oral solid agent of the invention on the leukemia model mice

[0041] Experimental animal and group administration

[0042] 615 Major mice, weighing 18-22 g (purchased from the Tianjin Hematology Research Institute), and gives subcutaneous injection of L615K lymphocyte leukemia cells (purchased from Tianjin Hematology Research Institute) to form a lotus tumor mouse model.All mice are divided into 6 groups, each group of 5, each group is given the following healing drugs:

[0043] Black control group: an equal volume of the volume

[0044] Group A group A: 2.5mg / kg Dashantinib

[0045] Dashaidinib group B: 5mg / kg Dusacinib

[0046] Solid Thistle Sumulin group A: 10mg / kg water pistol

[0047] Water Flying Tosin Group B: 20 mg / kg water pistol

[0048] Group A group A: 2.5mg / kg Dashantinib+ 10mg / kg water flying thistle

[0049] Group B group B: 2.5mg / kg Dashaidib+ 20mg / kg water flying thistle

[0050] Group C group C: 5mg / ml Dashaidinib+ ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to oral solid preparation for the treatment of leukemia. Pharmaceutical active ingredients of the preparation include Dasatinib and Silymarin. The oral solid preparation has the effect of significantly inhibiting the growth of acute promyelocytic leukemia NK4 cells, chronic granulocytic leukemia K562 cells and retinoic-acid-resistant promyelocytic leukemia MR-2 cells; the two pharmaceutical active ingredients have significant synergistic effect for the treatment of leukemia. In addition, the oral solid preparation has the advantages of ingredient clearness, low toxic and side effects and good treatment effect, and is suitable for the clinical popularization in the treatment of leukemia.

Description

Technical field [0001] The present invention is a pharmaceutical technology field, which involves a oral solid -solid preparation and application that treats leukemia. Background technique [0002] At present, cancer is one of the main diseases that seriously affect human health and threaten human life.Together with cardiovascular and cerebrovascular diseases and accidents, cancer constitutes three causes of death in all countries in the world today.Therefore, the World Health Organization and the governments of various countries have listed cancer as a primary task.There are three main methods of treating leukemia in the world. One is to use surgical resection to remove lesions to prevent cancer cells from spreading. Instead, chemotherapy or radiotherapy is used to kill cancer cells; third, drug treatment.The method of surgical resection increases the patient's pain, hurting its vitality, and the cost is huge.The method of radiotherapy, while killing cancer cells, also hurts red...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61P35/02A61K31/357
Inventor 张素平
Owner 北京贝思康医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap